Company: AZN
Filing Date: 2025-07-14
Form Type: 6-K
Source: 0001654954-25-008010
Chunk: 3

Company: ASTRAZENECA PLC
Filing Date: 2025-07-14
Form: 6-K
Chunk 3
---
 seated SBP less than 130 mmHg at Week 12 and occurrence of adverse events.

#### Baxdrostat
Baxdrostat is a potential first-in-class, highly selective and potent, oral, small molecule that inhibits aldosterone synthase, 15 an enzyme encoded by the CYP11B2 gene, which is responsible for the synthesis of aldosterone in the adrenal gland. 5 In clinical trials, baxdrostat was observed to significantly lower aldosterone levels without affecting cortisol levels across a wide range of doses. 16,17 Baxdrostat is currently being investigated in clinical trials as a monotherapy for hypertension 7-9 and primary aldosteronism, 10 and in combination with dapagliflozin for chronic kidney disease 11,12 and the prevention of heart failure in hypertensive patients. 13

AstraZeneca acquired baxdrostat through its purchase of CinCor Pharma, Inc. in February 2023. 18 A contingent value right of $10 per share in cash ($0.5 billion) is payable to former CinCor shareholders upon the submission of a new drug application either in the US or Europe. 18

#### AstraZeneca in CVRM
Cardiovascular, Renal and Metabolism (CVRM), part of BioPharmaceuticals, forms one of AstraZeneca’s main disease areas and is a key growth driver for the Company. By following the science to understand more clearly the underlying links between the heart, kidneys, liver and pancreas, AstraZeneca is investing in a portfolio of medicines for organ protection by slowing or stopping disease progression, and ultimately paving the way towards regenerative therapies. The Company’s ambition is to improve and save the lives of millions of people, by better understanding the interconnections between CVRM diseases and targeting the mechanisms that drive them, so we can detect, diagnose and treat people earlier and more effectively.

#### AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astr